Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)

Lessons from an international trial evaluating vaccination strategies for recovered inpatients with COVID-19 (VATICO)

The protection provided by natural versus hybrid immunity from COVID-19 is unclear. We reflect on the challenges from trying to conduct a randomized post-SARS-CoV-2 infection vaccination trial study with rapidly evolving scientific data, vaccination guidelines, varying international policies, diffic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Med (New York, N.Y. : Online) N.Y. : Online), 2022-08, Vol.3 (8), p.531-537
Hauptverfasser: Mylonakis, Eleftherios, Lutaakome, Joseph, Jain, Mamta K., Rogers, Angela J., Moltó, José, Benet, Susana, Mourad, Ahmad, Files, D. Clark, Mugerwa, Henry, Kityo, Cissy, Kiweewa, Francis, Nalubega, Mary Grace, Kitonsa, Jonathan, Nabenkema, Evelyn, Murray, Daniel D., Braun, Dominique, Kamel, Dena, Higgs, Elizabeth S., Hatlen, Timothy J., Kan, Virginia L., Sanchez, Adriana, Tierney, John, Denner, Eileen, Wentworth, Deborah, Babiker, Abdel G., Davey, Victoria J., Gelijns, Annetine C., Matthews, Gail V., Thompson, B. Taylor, Lane, H. Clifford, Neaton, James D., Lundgren, Jens D.
Format: Artikel
Sprache:eng
Schlagworte:
COVID-19 - prevention & control
COVID-19 - therapy
COVID-19 Vaccines
Humans
Inpatients
Randomized Controlled Trials as Topic
Vaccination - methods
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The protection provided by natural versus hybrid immunity from COVID-19 is unclear. We reflect on the challenges from trying to conduct a randomized post-SARS-CoV-2 infection vaccination trial study with rapidly evolving scientific data, vaccination guidelines, varying international policies, difficulties with vaccine availability, vaccine hesitancy, and a constantly evolving virus. The protection provided by natural versus hybrid immunity from COVID-19 is unclear. We reflect on the challenges from trying to conduct a randomized post-SARS-CoV-2 infection vaccination trial study with rapidly evolving scientific data, vaccination guidelines, varying international policies, difficulties with vaccine availability, vaccine hesitancy, and a constantly evolving virus.
ISSN:2666-6340
2666-6359
2666-6340
DOI:10.1016/j.medj.2022.07.003